Industry cloud solutions provider Veeva Systems Inc (NYSE: VEEV) reported second-quarter FY22 revenue growth of 29% year-on-year to $455.6 million beating the analyst…
Gainers
INmune Bio (NASDAQ: INMB) shares are trading higher after the company announced XPro has been found to decrease multiple species of Phospho Tau and improve neuroimaging biomarkers of myelination in patients with AD.
inancial Outlook:
Veeva is providing guidance for its fiscal third quarter ending October 31, 2021 as follows:
Total revenues between $464 and $466 million.
Non-GAAP operating income between $179 and $181
Veeva Systems (NYSE:VEEV) reported quarterly earnings of $0.94 per share which beat the analyst consensus estimate of $0.87 by 8.05 percent. This is a 30.56 percent increase over earnings of $0.72 per share from the same